ORD_59318/2024

TRANSCUTANEOUS ANALYTE SENSOR SYSTEMS AND METHODS

Prozessuale & UnteranträgeVerfahrensführungsanordnungenDusseldorf LDGeneric Order—

Übersicht Entscheidungen Dokumente Zeitverlauf

Parteien

Kläger

Dexcom Inc.(Dexcom Group)

Vertreter: Markus Grosch (Quinn Emanuel Urquhart & Sullivan LLP); Johannes Bukow (Quinn Emanuel Urquhart & Sullivan LLP); Jan Axtmann (Quinn Emanuel Urquhart & Sullivan LLP); Paul Lehmann (Quinn Emanuel Urquhart & Sullivan LLP)

Beklagte

Abbott Logistics B.V.(Abbott Group)
Abbott Laboratories GmbH(Abbott Group)
Abbott Laboratories(Abbott Group)
Abbott Oy(Abbott Group)
Abbott Scandinavia Aktiebolag(Abbott Group)
Abbott (S.A./N.V.)(Abbott Group)
Abbott B.V.(Abbott Group)
Abbott France (S.A.S.)(Abbott Group)
Abbott GmbH(Abbott Group)
Abbott Diagnostics GmbH(Abbott Group)
Abbott Gesellschaft m.b.H.(Abbott Group)
Abbott Diabetes Care Inc.(Abbott Group)
Abbott s.r.l.(Abbott Group)

Vertreter: Dietrich Kamlah (Taylor Wessing); Christian Lederer (Taylor Wessing); Gisbert Hohagen (Taylor Wessing)

Richter

ThomasPresiding Judge / Judge-Rapporteur
ThomLegally Qualified Judge
RinkinenLegally Qualified Judge

Patente

EP 4 026 488

CPC-Codes: A61B5/6849, A61B2560/063, A61B5/14865, A61B5/688, A61B5/14532, A61B5/14546, A61B5/6848, A61B5/6832, A61B5/68335, A61B2562/222, A61B2562/227, A61B2560/045…

Sektor: Pharmaceutical & Medical

Ausgang

Nur prozessual

Eingereicht: —

Erste Entscheidung: 21. Nov. 2024

Sprache: —